Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga- and 18F-Labeled CAIX-Targeted PET/CT Imaging in Patients With Renal Tumors
NCT07875946Phase 1Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Oct 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in renal cell carcinoma (RCC) and renal tumor comparing 68Ga-CAIX PET/CT with 18F-CAIX PET/CT (2 arms). Primary endpoint: Semiquantitative Uptake of CAIX-Targeted Tracers at 60 minutes. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
68Ga-CAIX18F-CAIX
03
Conditions
renal cell carcinoma (RCC)renal tumor
Beyond the preview
Go deeper on NCT07875946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07875946.